SMP201100019B - Composti organici - Google Patents

Composti organici

Info

Publication number: SMP201100019B
Authority: SM; San Marino
Prior art keywords: organic compounds; compounds; phosphatidylinositol; kinase; substituents
Prior art date: 2008-09-10

Application number

SM201100019T

Other languages

English (en)

Other versions

SMAP201100019A (it

Inventor

Pascal Furet

Vito Guagnano

Giorgio Caravatti

Robin Alec Fairhurst

Patricia Imbach

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-10

Filing date

2011-04-07

Publication date

2012-01-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40350060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMP201100019(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-04-07 Application filed by Novartis Ag filed Critical Novartis Ag

2011-05-06 Publication of SMAP201100019A publication Critical patent/SMAP201100019A/it

2012-01-18 Publication of SMP201100019B publication Critical patent/SMP201100019B/it

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Hematology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)

SM201100019T 2008-09-10 2011-04-07 Composti organici SMP201100019B (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08164104		2008-09-10
US9667408P	2008-09-12	2008-09-12
PCT/EP2009/061644 WO2010029082A1 (en)	2008-09-10	2009-09-08	Organic compounds

Publications (2)

Publication Number	Publication Date
SMAP201100019A SMAP201100019A (it)	2011-05-06
SMP201100019B true SMP201100019B (it)	2012-01-18

Family

ID=40350060

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM201100019T SMP201100019B (it)	2008-09-10	2011-04-07	Composti organici

Country Status (50)

Country	Link
US (4)	US8227462B2 (it)
EP (1)	EP2331537B1 (it)
JP (1)	JP5486601B2 (it)
KR (1)	KR101290844B1 (it)
CN (1)	CN102149711B (it)
AR (2)	AR073369A1 (it)
AU (1)	AU2009290904B2 (it)
BR (1)	BRPI0918750B8 (it)
CA (1)	CA2734819C (it)
CL (1)	CL2011000504A1 (it)
CO (1)	CO6351738A2 (it)
CR (1)	CR20110059A (it)
CU (1)	CU24000B1 (it)
CY (2)	CY1117078T1 (it)
DK (1)	DK2331537T3 (it)
DO (1)	DOP2011000070A (it)
EA (1)	EA018863B1 (it)
EC (1)	ECSP11010880A (it)
ES (1)	ES2560673T3 (it)
FI (1)	FIC20200046I1 (it)
GE (1)	GEP20135991B (it)
HN (1)	HN2011000699A (it)
HR (1)	HRP20160014T1 (it)
HU (2)	HUE025884T2 (it)
IL (1)	IL210976A (it)
JO (1)	JO3121B1 (it)
LT (1)	LTC2331537I2 (it)
LU (1)	LUC00186I2 (it)
MA (1)	MA32604B1 (it)
ME (1)	ME01284B (it)
MX (1)	MX2011002597A (it)
MY (1)	MY151556A (it)
NI (1)	NI201100049A (it)
NL (1)	NL301071I2 (it)
NO (1)	NO2020037I1 (it)
NZ (1)	NZ590754A (it)
PA (1)	PA8841901A1 (it)
PE (1)	PE20110796A1 (it)
PL (1)	PL2331537T3 (it)
PT (1)	PT2331537E (it)
RS (1)	RS54476B1 (it)
SI (1)	SI2331537T1 (it)
SM (1)	SMP201100019B (it)
SV (1)	SV2011003853A (it)
TN (1)	TN2011000053A1 (it)
TW (1)	TWI453206B (it)
UA (1)	UA104147C2 (it)
UY (1)	UY32096A (it)
WO (1)	WO2010029082A1 (it)
ZA (1)	ZA201100699B (it)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR044519A1 (es) *	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
BRPI0915901A2 (pt)	2008-07-11	2015-10-27	Novartis Ag	combinação de (a) um inibidor de fosfoinositídeo 3-quinase e (b) um modulador da via ras/raf/mek
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) *	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
CA2815492C (en) *	2010-11-08	2019-04-09	Novartis Ag	Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
AU2015203865B2 (en) *	2010-11-08	2016-11-03	Novartis Ag	Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
UA112539C2 (uk) *	2011-03-03	2016-09-26	Новартіс Аг	Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
NZ615593A (en) *	2011-04-25	2015-05-29	Novartis Ag	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
MX2013014887A (es)	2011-06-21	2014-02-17	Novartis Ag	Polimorfos de 1- ({4-metil-5- [2- (2 ,2 ,2-trifluoro-1,1-dimetil-e til) piridin-4-il] - tiazol-2-il}-amida de 2-amida del acido (s) -pirrolidin-1,2-dicarboxilico.
JP5832647B2 (ja) *	2011-07-01	2015-12-16	ノバルティスアーゲー	がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法
KR20140072028A (ko) *	2011-08-31	2014-06-12	노파르티스 아게	Pi3k- 및 mek-억제제의 상승작용적 조합물
US20140235630A1 (en) *	2011-09-30	2014-08-21	Beth Israel Deaconess Medical Center, Inc.	Compositions and methods for the treatment of proliferative diseases
MX2014004559A (es) *	2011-10-14	2014-08-01	Novartis Ag	Derivados de 2-carboxamida cicloamino urea en combinacion con inhibidores de hsp90 para el tratamiento de enfermedades proliferativas.
JP2014532647A (ja) *	2011-10-28	2014-12-08	ノバルティスアーゲー	消化管間質腫瘍を治療する方法
BR112014010233A2 (pt) *	2011-11-02	2017-04-18	Novartis Ag	derivados de 2-carboxamida cicloamino ureia para uso no tratamento de doenças dependentes de vegf
BR112014020773A2 (pt)	2012-02-22	2020-10-27	Sanford-Burnham Medical Research Institute	compostos de sulfonamida e seus usos como inibidores tnap
AU2013241752B2 (en) *	2012-03-29	2016-07-07	Novartis Ag	Pharmaceutical diagnostic
AU2013239624A1 (en) *	2012-03-30	2014-10-02	Novartis Ag	Compounds for use in the treatment of neuroblastoma, Ewing's Sarcoma or rhabdomyosarcoma
KR20160027217A (ko)	2012-05-23	2016-03-09	에프. 호프만-라 로슈 아게	내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8980259B2 (en)	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
MY176031A (en)	2012-08-07	2020-07-22	Array Biopharma Inc	Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
WO2014028566A1 (en) *	2012-08-16	2014-02-20	Novartis Ag	Combination of pi3k inhibitor and c-met inhibitor
SI2897644T1 (sl) *	2012-09-20	2018-10-30	Novartis Ag	Farmacevtska kombinacija, ki obsega fosfatidilinozitol 3-kinazni inhibitor in aromatazni inhibitor
WO2014075754A1 (en) *	2012-11-16	2014-05-22	Merck Patent Gmbh	3-aminocyclopentane carboxamide derivatives
EP3251673A1 (en)	2012-12-13	2017-12-06	IP Gesellschaft für Management mbH	Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
SG11201505631PA (en)	2013-01-23	2015-08-28	Astrazeneca Ab	Chemical compounds
MX2015011899A (es)	2013-03-15	2016-05-05	Genentech Inc	Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
WO2014147573A2 (en) *	2013-03-21	2014-09-25	Novartis Ag	Combination therapy
SG11201507720PA (en) *	2013-04-05	2015-10-29	Sanofi Sa	Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
EP3003377A1 (en)	2013-05-31	2016-04-13	Novartis AG	Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
WO2014199294A1 (en)	2013-06-11	2014-12-18	Novartis Ag	Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
CN105338980A (zh)	2013-06-18	2016-02-17	诺华股份有限公司	药物组合
HK1222539A1 (zh)	2013-08-08	2017-07-07	Novartis Ag	Pim激酶抑制剂组合
MX384403B (es)	2013-08-14	2025-03-14	Novartis Ag	Terapia de combinación para el tratamiento del cáncer.
WO2015048312A1 (en)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
CA2930359C (en) *	2013-12-06	2022-03-01	Novartis Ag	Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
JP2017502989A (ja) *	2014-01-15	2017-01-26	ノバルティスアーゲー	組合せ医薬
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR20160110963A (ko)	2014-02-11	2016-09-23	노파르티스 아게	암 치료를 위한 pi3k 억제제를 포함하는 제약 조합물
LT3116909T (lt)	2014-03-14	2020-02-10	Novartis Ag	Antikūno molekulės prieš lag-3 ir jų panaudojimas
CA2960824A1 (en)	2014-09-13	2016-03-17	Novartis Ag	Combination therapies of alk inhibitors
ES2774448T3 (es)	2014-10-03	2020-07-21	Novartis Ag	Terapias de combinación
JP6723229B2 (ja)	2014-10-03	2020-07-15	ノバルティスアーゲー	アルペリシブを含む医薬組成物
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6877339B2 (ja)	2014-10-14	2021-05-26	ノバルティスアーゲー	Ｐｄ−ｌ１に対する抗体分子およびその使用
CN104844589B (zh) *	2014-12-26	2018-04-20	中国科学院合肥物质科学研究院	一种pi3k激酶抑制剂
JP6692826B2 (ja)	2015-03-10	2020-05-13	アドゥロバイオテック，インク．	「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
US10130629B2 (en)	2015-03-25	2018-11-20	Novartis Ag	Pharmaceutical combinations
KR20180012324A (ko)	2015-06-29	2018-02-05	에프. 호프만-라 로슈 아게	타셀리십을 사용하는 치료 방법
PL3567045T3 (pl)	2015-07-02	2022-04-19	F. Hoffmann-La Roche Ag	Związki benzoksazepinooksazolidynonowe i sposoby zastosowania
WO2017019896A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en)	2015-07-29	2021-09-15	Novartis AG	Combination therapies comprising antibody molecules to tim-3
EP3964528A1 (en)	2015-07-29	2022-03-09	Novartis AG	Combination therapies comprising antibody molecules to lag-3
JP2018525425A (ja)	2015-08-28	2018-09-06	ノバルティスアーゲー	がんを治療または予防するためのリボシクリブとダブラフェニブの組み合わせ
WO2017037578A2 (en)	2015-08-28	2017-03-09	Novartis Ag	Combination therapy
CN108348514A (zh)	2015-08-28	2018-07-31	诺华股份有限公司	含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
JP2018528949A (ja)	2015-08-28	2018-10-04	ノバルティスアーゲー	Ｐｉ３ｋ阻害剤およびｍｄｍ２阻害剤を使用する組み合わせ療法
JP2018526377A (ja)	2015-08-28	2018-09-13	ノバルティスアーゲー	がんを治療するための、任意にｐｉ３ｋ阻害剤のｂｙｌ７１９を更に含む、ｃｄｋ４／６阻害剤のｌｅｅ０１１とｍｅｋ１／２阻害剤トラメチニブの組み合わせ物
CN108348520A (zh)	2015-08-28	2018-07-31	诺华股份有限公司	Mdm2抑制剂和其组合
TW201726140A (zh)	2015-09-17	2017-08-01	瑞典商阿斯特捷利康公司	治療癌症之新型生物標記及方法
CN105294546B (zh) *	2015-10-29	2017-12-08	天津市斯芬克司药物研发有限公司	一种吡啶化合物及其制备方法
CN108472289A (zh)	2015-11-02	2018-08-31	诺华股份有限公司	磷脂酰肌醇3-激酶抑制剂的给药方案
LT3370768T (lt)	2015-11-03	2022-05-25	Janssen Biotech, Inc.	Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
MX2018006777A (es)	2015-12-03	2018-08-01	Novartis Ag	Tratamiento de cancer con un inhibidor de pi3k en un paciente previamente seleccionado por tener una mutacion de pik3ca en el ctadn.
EP4424322A3 (en)	2015-12-17	2025-04-16	Novartis AG	Antibody molecules to pd-1 and uses thereof
WO2018009466A1 (en)	2016-07-05	2018-01-11	Aduro Biotech, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018060833A1 (en)	2016-09-27	2018-04-05	Novartis Ag	Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018092064A1 (en)	2016-11-18	2018-05-24	Novartis Ag	Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN106674200B (zh) *	2016-12-21	2019-04-12	西安交通大学	一种含有l-脯氨酰胺片段的化合物及其制备方法和应用
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en)	2017-06-22	2020-04-29	Novartis AG	Antibody molecules to cd73 and uses thereof
US11312783B2 (en)	2017-06-22	2022-04-26	Novartis Ag	Antibody molecules to CD73 and uses thereof
US11351156B2 (en)	2017-10-13	2022-06-07	Inserm	Combination treatment of pancreatic cancer
WO2019101871A1 (en)	2017-11-23	2019-05-31	Inserm (Institut National De La Sante Et De La Recherche Medicale)	A new marker for predicting the sensitivity to pi3k inhibitors
CN111386113A (zh)	2017-12-01	2020-07-07	诺华股份有限公司	包含lsz102和阿培利司的药物组合
US11465985B2 (en) *	2017-12-08	2022-10-11	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
SMT202200134T1 (it)	2018-03-08	2022-05-12	Incyte Corp	Composti di amminopirazindiolo come inibitori di pi3k-y
KR102765889B1 (ko)	2018-05-30	2025-02-11	장쑤 한서 파마슈티칼 그룹 캄파니 리미티드	트리사이클릭 유도체를 함유하는 억제제, 이를 위한 제조 방법, 및 이의 적용
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
US20220047567A1 (en) *	2018-09-10	2022-02-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of neurofibromatosis
EP3860597A4 (en) *	2018-10-05	2022-08-17	Sloan-Kettering Institute for Cancer Research	PI3K INHIBITORS AND USES THEREOF
KR20210107069A (ko)	2018-12-21	2021-08-31	다이이찌 산쿄 가부시키가이샤	항체-약물 컨쥬게이트와 키나아제 저해제의 조합
CN113874362A (zh)	2019-05-13	2021-12-31	罗欣健康科技发展(北京)有限公司	喹唑啉酮类化合物的晶型及其制备方法
CN120172965A (zh) *	2019-05-27	2025-06-20	君实润佳(上海)医药科技有限公司	含有稳定重同位素的酰胺官能团的化合物及其应用
US20220354863A1 (en)	2019-07-02	2022-11-10	Inserm (Institut National De La Santè Et De La Recherch Médicale)	Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
WO2021001431A1 (en)	2019-07-02	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer
US20220354452A1 (en)	2019-07-02	2022-11-10	Inserm (Institut National De La Santé Et De La Rechrche Médical)	Use of ultrafast elasticity imaging for detecting pancreatic cancers
JP7616794B2 (ja)	2019-07-07	2025-01-17	オレマファーマシューティカルズインク．	エストロゲン受容体アンタゴニストのレジメン
MX2022002415A (es)	2019-08-26	2022-03-22	Arvinas Operations Inc	Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
KR20220119610A (ko)	2019-11-25	2022-08-30	상하이 한서 바이오메디컬 컴퍼니 리미티드	3개의 융합된 고리 유도체-함유 염 또는 결정 형태 및 이의 약학 조성물
CN113045564B (zh) *	2019-12-27	2024-09-20	上海天慈国际药业有限公司	一种阿培利司的制备方法
EP4126815A1 (en)	2020-03-25	2023-02-08	Risen (Suzhou) Pharma Tech Co., Ltd.	Stable heavy isotopes in amide functional groups and uses thereof
WO2022016420A1 (zh) *	2020-07-22	2022-01-27	罗欣药业(上海)有限公司	一种喹唑啉酮类化合物的晶型、其制备方法及应用
CN117279627A (zh)	2021-05-03	2023-12-22	诺华股份有限公司	阿培利司配制品
CN115611883B (zh) *	2021-07-13	2025-03-28	生物岛实验室	一种双环结构的PI3Kα抑制剂及其制备方法和用途
JP2024537139A (ja)	2021-10-05	2024-10-10	ミラティセラピューティクス，インコーポレイテッド	ＫＲＡＳＧ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法
CN118201922A (zh) *	2021-11-12	2024-06-14	百极优棠(广东)医药科技有限公司	Drak2抑制剂及其制备方法和应用
EP4230196A1 (en)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Compounds for use in the treatment of dystrophinopathies
KR20250097910A (ko)	2022-10-28	2025-06-30	인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인쎄름)	포스파티딜이노시톨 3-키나제의 신규 억제제
CN120187416A (zh)	2022-11-11	2025-06-20	阿斯利康(瑞典)有限公司	用于治疗癌症的组合疗法
CN116239591B (zh) *	2023-02-14	2025-09-23	嘉兴大学	一种(4r)-磺酰氨基-l-脯氨酰胺类化合物、制备方法、应用及其药物组合
WO2024206147A1 (en)	2023-03-24	2024-10-03	Arvinas Operations, Inc.	Dosage regimens of estrogen receptor degraders
CN116987072A (zh) *	2023-07-27	2023-11-03	武汉呈瑞生物医药科技有限公司	化合物及其应用
WO2025181153A1 (en)	2024-03-01	2025-09-04	F. Hoffmann-La Roche Ag	Use of atr inhibitors in combination with pi3k alpha inhibitors
EP4643858A1 (en) *	2024-04-29	2025-11-05	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical composition for the treatment of uterine disease

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4649146A (en) *	1983-01-31	1987-03-10	Fujisawa Pharmaceutical Co., Ltd.	Thiazole derivatives and pharmaceutical composition comprising the same
DE3703435A1 (de)	1987-02-05	1988-08-18	Thomae Gmbh Dr K	Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5229402A (en)	1988-04-15	1993-07-20	Taiho Pharmaceutical Company, Ltd.	Carbamoyl-2-pyrrolidinone compounds
US5028726A (en) *	1990-02-07	1991-07-02	The University Of Vermont And State Agricultural College	Platinum amine sulfoxide complexes
US5780653A (en) *	1995-06-07	1998-07-14	Vivorx Pharmaceuticals, Inc.	Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
JP2001505585A (ja)	1996-12-16	2001-04-24	藤沢薬品工業株式会社	新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
US6187797B1 (en) *	1996-12-23	2001-02-13	Dupont Pharmaceuticals Company	Phenyl-isoxazoles as factor XA Inhibitors
ATE427353T1 (de) *	1997-02-10	2009-04-15	Genentech Inc	Heregulin varianten
ATE257703T1 (de)	1997-10-27	2004-01-15	Takeda Chemical Industries Ltd	1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
ATE288904T1 (de)	1998-06-18	2005-02-15	Bristol Myers Squibb Co	Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
HUP0202682A3 (en) *	1999-09-10	2003-03-28	Merck & Co Inc	Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
IL151946A0 (en) *	2000-03-29	2003-04-10	Cyclacel Ltd	2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
DE60134679D1 (de)	2000-10-20	2008-08-14	Eisai R&D Man Co Ltd	Stickstoff enthaltende aromatische Heterozyklen
EP1256578B1 (en)	2001-05-11	2006-01-11	Pfizer Products Inc.	Thiazole derivatives and their use as cdk inhibitors
IL160329A0 (en) *	2001-08-13	2004-07-25	Janssen Pharmaceutica Nv	2-amino-4,5-trisubstituted thiazolyl derivatives
WO2003015778A1 (en)	2001-08-17	2003-02-27	Merck & Co., Inc.	Tyrosine kinase inhibitors
NZ531596A (en) *	2001-09-28	2005-08-26	Cyclacel Ltd	N-(4-(4-methylthiazol-5-YL) pyrimidin-2-YL) -N- phenylamine compounds used in the treatment of proliferative disorders such as cancer
AR038703A1 (es) *	2002-02-28	2005-01-26	Novartis Ag	Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
AU2003288956A1 (en) *	2002-10-30	2004-06-07	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of rock and other protein kinases
EP1567487A4 (en)	2002-11-15	2005-11-16	Bristol Myers Squibb Co	OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
AU2004204778B2 (en) *	2003-01-10	2008-05-22	Threshold Pharmaceuticals, Inc.	Treatment of cancer with 2-deoxyglucose
GB0305152D0 (en)	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
AR044519A1 (es) *	2003-05-02	2005-09-14	Novartis Ag	Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0320197D0 (en) *	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
AU2004272599A1 (en)	2003-09-06	2005-03-24	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
EP1709019B1 (en)	2004-01-12	2007-08-08	Applied Research Systems ARS Holding N.V.	Thiazole derivatives and use thereof
AU2005260032A1 (en) *	2004-06-29	2006-01-12	Amgen Inc.	Pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity
SE0402735D0 (sv) *	2004-11-09	2004-11-09	Astrazeneca Ab	Novel compounds
BRPI0607809A2 (pt) *	2005-02-18	2009-06-13	Abraxis Bioscience Inc	uso de uma composição compreendendo nanopartìculas, composição e kit
DE102005024157A1 (de)	2005-05-23	2006-11-30	Amedo Gmbh	Nadelpositioniersystem
MX2007014886A (es)	2005-05-24	2008-02-19	Serono Lab	Derivados de tiazol y uso de los mismos.
KR20080015119A (ko)	2005-05-24	2008-02-18	라보라뚜와르 세로노 에스. 에이.	티아졸 유도체 및 그의 용도
DE102005024790A1 (de)	2005-05-26	2006-12-07	Eos Gmbh Electro Optical Systems	Strahlungsheizung zum Heizen des Aufbaumaterials in einer Lasersintervorrichtung
US7655446B2 (en) *	2005-06-28	2010-02-02	Vertex Pharmaceuticals Incorporated	Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof
DE102005048072A1 (de)	2005-09-24	2007-04-05	Bayer Cropscience Ag	Thiazole als Fungizide
AU2006326443A1 (en)	2005-12-12	2007-06-21	Genelabs Technologies, Inc.	N-(5-membered heteroaromatic ring)-amido anti-viral compounds
GB0525671D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
WO2007082956A1 (en) *	2006-01-23	2007-07-26	Laboratoires Serono S.A.	Thiazole derivatives and use thereof
US20070259855A1 (en) *	2006-04-06	2007-11-08	Udo Maier	Thiazolyl-dihydro-indazole
EP2016075A1 (en) *	2006-05-03	2009-01-21	AstraZeneca AB	Thiazole derivatives and their use as anti-tumour agents
GB0610243D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
GB0612630D0 (en) *	2006-06-26	2006-08-02	Novartis Ag	Organic compounds
FR2904190B1 (fr)	2006-07-25	2008-12-12	Inst Rech Pour Le Dev I R D Et	Utilisation d'inocula fongiques pour l'amelioration de la production maraichere
WO2008064218A2 (en)	2006-11-21	2008-05-29	Smithkline Beecham Corporation	Amido anti-viral compounds
WO2008124000A2 (en)	2007-04-02	2008-10-16	Ligand Pharmaceuticals Incorporated	Thiazole derivatives as androgen receptor modulator compounds
TWI443090B (zh)	2007-05-25	2014-07-01	Abbvie Deutschland	作為代謝性麩胺酸受體２（ｍｇｌｕ２受體）之正向調節劑之雜環化合物
US20090004140A1 (en)	2007-06-26	2009-01-01	Yao-Ling Qiu	4-substituted pyrrolidine as anti-infectives
JP2010533736A (ja)	2007-07-19	2010-10-28	ハー・ルンドベック・アクチエゼルスカベット	５員複素環アミドおよび関連化合物
ITMI20072396A1 (it)	2007-12-20	2009-06-21	Dachi S R L	"apparato di chiusura di contenitori di materiale biologico"
UY31545A1 (es) *	2007-12-20	2009-08-03		Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
JP2011506563A (ja)	2007-12-20	2011-03-03	ノバルティスアーゲー	ビスチアゾール誘導体、その製造方法および医薬品としてのその使用
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань

2009
- 2009-08-09 UA UAA201102837A patent/UA104147C2/uk unknown
- 2009-09-08 SI SI200931344T patent/SI2331537T1/sl unknown
- 2009-09-08 CA CA2734819A patent/CA2734819C/en active Active
- 2009-09-08 PT PT97827778T patent/PT2331537E/pt unknown
- 2009-09-08 MY MYPI20110510 patent/MY151556A/en unknown
- 2009-09-08 UY UY0001032096A patent/UY32096A/es active IP Right Grant
- 2009-09-08 BR BRPI0918750A patent/BRPI0918750B8/pt active IP Right Grant
- 2009-09-08 GE GEAP200912132A patent/GEP20135991B/en unknown
- 2009-09-08 MX MX2011002597A patent/MX2011002597A/es active IP Right Grant
- 2009-09-08 AU AU2009290904A patent/AU2009290904B2/en active Active
- 2009-09-08 PE PE2011000591A patent/PE20110796A1/es active IP Right Grant
- 2009-09-08 EP EP09782777.8A patent/EP2331537B1/en active Active
- 2009-09-08 PL PL09782777T patent/PL2331537T3/pl unknown
- 2009-09-08 ME MEP-2011-21A patent/ME01284B/me unknown
- 2009-09-08 EA EA201100447A patent/EA018863B1/ru active Protection Beyond IP Right Term
- 2009-09-08 DK DK09782777.8T patent/DK2331537T3/en active
- 2009-09-08 JP JP2011526479A patent/JP5486601B2/ja active Active
- 2009-09-08 HR HRP20160014TT patent/HRP20160014T1/hr unknown
- 2009-09-08 CN CN200980135415.7A patent/CN102149711B/zh active Active
- 2009-09-08 ES ES09782777.8T patent/ES2560673T3/es active Active
- 2009-09-08 RS RS20150860A patent/RS54476B1/sr unknown
- 2009-09-08 AR ARP090103437A patent/AR073369A1/es not_active Application Discontinuation
- 2009-09-08 KR KR1020117005524A patent/KR101290844B1/ko active Active
- 2009-09-08 NZ NZ590754A patent/NZ590754A/xx unknown
- 2009-09-08 WO PCT/EP2009/061644 patent/WO2010029082A1/en not_active Ceased
- 2009-09-08 HU HUE09782777A patent/HUE025884T2/en unknown
- 2009-09-09 TW TW098130412A patent/TWI453206B/zh active
- 2009-09-09 JO JOP/2009/0334A patent/JO3121B1/ar active
- 2009-09-10 US US12/556,964 patent/US8227462B2/en active Active
- 2009-09-10 PA PA20098841901A patent/PA8841901A1/es unknown
2011
- 2011-01-27 ZA ZA2011/00699A patent/ZA201100699B/en unknown
- 2011-01-31 TN TN2011000053A patent/TN2011000053A1/fr unknown
- 2011-01-31 IL IL210976A patent/IL210976A/en active IP Right Grant
- 2011-02-01 CR CR20110059A patent/CR20110059A/es unknown
- 2011-03-01 MA MA33661A patent/MA32604B1/fr unknown
- 2011-03-07 DO DO2011000070A patent/DOP2011000070A/es unknown
- 2011-03-08 HN HN2011000699A patent/HN2011000699A/es unknown
- 2011-03-09 CL CL2011000504A patent/CL2011000504A1/es unknown
- 2011-03-09 NI NI201100049A patent/NI201100049A/es unknown
- 2011-03-10 EC EC2011010880A patent/ECSP11010880A/es unknown
- 2011-03-10 SV SV2011003853A patent/SV2011003853A/es unknown
- 2011-03-10 CU CU2011000052A patent/CU24000B1/es active IP Right Grant
- 2011-03-17 CO CO11033546A patent/CO6351738A2/es active IP Right Grant
- 2011-04-07 SM SM201100019T patent/SMP201100019B/it unknown
2012
- 2012-06-05 US US13/488,589 patent/US8476268B2/en active Active
2013
- 2013-05-24 US US13/901,930 patent/US8710085B2/en active Active
2014
- 2014-02-27 US US14/192,633 patent/US20140186469A1/en not_active Abandoned
2015
- 2015-12-29 CY CY20151101197T patent/CY1117078T1/el unknown
2018
- 2018-06-06 AR ARP180101520A patent/AR112074A2/es not_active Application Discontinuation
2020
- 2020-11-06 NL NL301071C patent/NL301071I2/nl unknown
- 2020-11-16 NO NO2020037C patent/NO2020037I1/no unknown
- 2020-11-18 HU HUS2000044C patent/HUS2000044I1/hu unknown
- 2020-11-20 LU LU00186C patent/LUC00186I2/fr unknown
- 2020-11-24 CY CY2020037C patent/CY2020037I1/el unknown
- 2020-11-25 LT LTPA2020534C patent/LTC2331537I2/lt unknown
- 2020-11-26 FI FIC20200046C patent/FIC20200046I1/fi unknown

Also Published As

Publication number	Publication date
PL2331537T3 (pl)	2016-06-30
LUC00186I2 (it)	2024-07-01
CU24000B1 (es)	2014-06-27
PA8841901A1 (es)	2010-06-28
WO2010029082A1 (en)	2010-03-18
JP5486601B2 (ja)	2014-05-07
CA2734819A1 (en)	2010-03-18
DOP2011000070A (es)	2011-03-31
IL210976A0 (en)	2011-04-28
SI2331537T1 (sl)	2016-02-29
GEP20135991B (en)	2013-12-25
EP2331537A1 (en)	2011-06-15
NI201100049A (es)	2011-07-26
TN2011000053A1 (en)	2012-09-05
RS54476B1 (sr)	2016-06-30
AR073369A1 (es)	2010-11-03
ES2560673T3 (es)	2016-02-22
CY2020037I2 (el)	2021-03-12
BRPI0918750B8 (pt)	2021-05-25
EA018863B1 (ru)	2013-11-29
NO2020037I1 (no)	2020-11-16
US8476268B2 (en)	2013-07-02
NL301071I2 (nl)	2020-12-01
US8710085B2 (en)	2014-04-29
HUE025884T2 (en)	2016-05-30
AR112074A2 (es)	2019-09-18
KR20110038737A (ko)	2011-04-14
US20140005232A1 (en)	2014-01-02
DK2331537T3 (en)	2016-01-25
CN102149711B (zh)	2014-09-10
SMAP201100019A (it)	2011-05-06
CR20110059A (es)	2011-03-28
NZ590754A (en)	2012-08-31
CN102149711A (zh)	2011-08-10
EP2331537B1 (en)	2015-10-28
JO3121B1 (ar)	2017-09-20
EA201100447A1 (ru)	2011-10-31
ZA201100699B (en)	2012-08-29
CA2734819C (en)	2017-10-24
PT2331537E (pt)	2016-03-03
KR101290844B1 (ko)	2013-07-29
US8227462B2 (en)	2012-07-24
JP2012502080A (ja)	2012-01-26
MY151556A (en)	2014-06-13
FIC20200046I1 (fi)	2020-11-26
MA32604B1 (fr)	2011-09-01
US20120263712A1 (en)	2012-10-18
AU2009290904B2 (en)	2012-08-30
UA104147C2 (uk)	2014-01-10
CY2020037I1 (el)	2021-03-12
AU2009290904A1 (en)	2010-03-18
PE20110796A1 (es)	2011-11-04
US20100105711A1 (en)	2010-04-29
LTC2331537I2 (lt)	2022-01-10
ECSP11010880A (es)	2011-04-29
CU20110052A7 (es)	2011-12-28
IL210976A (en)	2014-09-30
MX2011002597A (es)	2011-07-21
LTPA2020534I1 (lt)	2020-12-28
HK1156305A1 (en)	2012-06-08
TW201014851A (en)	2010-04-16
SV2011003853A (es)	2011-05-16
CY1117078T1 (el)	2017-04-05
BRPI0918750A2 (pt)	2020-08-04
NL301071I1 (nl)	2020-11-11
CO6351738A2 (es)	2011-12-20
ME01284B (me)	2013-06-20
TWI453206B (zh)	2014-09-21
US20140186469A1 (en)	2014-07-03
BRPI0918750B1 (pt)	2020-12-22
HUS2000044I1 (hu)	2020-12-28
CL2011000504A1 (es)	2011-07-15
UY32096A (es)	2010-04-30
HRP20160014T1 (hr)	2016-02-12
HN2011000699A (es)	2013-12-02

Publication	Publication Date	Title
SMAP201100019A (it)	2011-05-06	Composti organici.
TN2010000293A1 (en)	2011-11-11	Thiazole derivatives used as pi 3 kinase inhibitors
MX2012000177A (es)	2012-02-28	2-carboxamida-cicloamino-ureas sustituidas.
BRPI1009637A2 (pt)	2019-04-30	composto, composição e uso de um composto
DK2074120T3 (da)	2010-06-14	Tropan-forbindelser
EA201201648A1 (ru)	2013-06-28	Стимуляторы sgc
ATE522536T1 (de)	2011-09-15	Pyrrolopyrazin-kinasehemmer
UA107445C2 (uk)	2015-01-12	5-фторпіримідинові похідні як фунгіциди
TN2010000038A1 (en)	2011-09-26	Organic compounds
EA201201377A1 (ru)	2013-04-30	Определенные аминопиридазины, композиции на их основе и способы их использования
EA201001682A1 (ru)	2011-06-30	Производные фенил- и бензодиоксинилзамещенных индазолов
EA201000113A1 (ru)	2010-08-30	Пиразольные соединения
EP3586631A3 (en)	2020-03-18	Plant health composition
ATE554066T1 (de)	2012-05-15	Entzündungshemmende substituierte cyclobutendionverbindungen
ATE517873T1 (de)	2011-08-15	6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
MX2008016358A (es)	2009-01-16	Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
MX2012000178A (es)	2012-02-28	2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k.
NZ591837A (en)	2013-03-28	Amino acid derivative
ATE481395T1 (de)	2010-10-15	Cyclohexylderivate
GB0602951D0 (en)	2006-03-29	Organic Compounds
EA201270311A1 (ru)	2012-09-28	Конденсированное гетероциклическое производное и его применение
EA200702590A1 (ru)	2008-06-30	Ингибиторы растворимой аденилатциклазы
ATE522530T1 (de)	2011-09-15	2-piperazin-1-yl-3h-imidazoä4,5-bü- pyridinderivate
CU20100127A7 (es)	2011-10-31	Derivados de tiazol usados como inhibidores de pi 3-cinasa
EA201101652A1 (ru)	2012-07-30	Антиоомицеты